Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in T2DM and CKD: A Secondary Analysis of the SCORED Trial

Vikas S. Sridhar,Deepak L. Bhatt,Ayodele Odutayo,Michael Szarek,Michael J. Davies,Phillip Banks,Bertram Pitt,Ph. Gabriel Steg,David Z. I. Cherney

DOI: https://doi.org/10.2215/cjn.0000000000000414

IF: 10.6233

2024-01-26

Clinical Journal of the American Society of Nephrology

Abstract:Introduction: In the initial analysis of SCORED, due to early trial termination and suspension of adjudication, reconciliation of eGFR laboratory data and case report forms had not been completed. This resulted in a small number of kidney composite events and a nominal effect of sotagliflozin versus placebo on this outcome. This exploratory analysis uses laboratory eGFR data, regardless of case report form completion, to assess the effects of sotagliflozin on the predefined kidney composite endpoint in SCORED and additional cardiorenal composite endpoints. Methods: SCORED was a multicenter, randomized trial evaluating cardiorenal outcomes with sotagliflozin versus placebo in 10,584 patients with type 2 diabetes and chronic kidney disease (CKD). The present exploratory analyses used laboratory data to derive the eGFR components and case report form data for the non-laboratory defined components that together made up the kidney and cardiorenal composites. Acute kidney injury (AKI) was also assessed in this dataset. Results: Using laboratory data, 223 events were identified and sotagliflozin reduced the risk of the composite of first event of sustained ≥50% decline in eGFR, eGFR<15 mL/min/1.73m2, dialysis, or kidney transplant with 87 events (1.6%) in the sotagliflozin group and 136 events (2.6%) in the placebo group (HR [95% CI] = 0.62 [0.48, 0.82]), p<0.001). Sotagliflozin reduced the risk of a cardiorenal composite endpoint defined as the above composite plus cardiovascular or kidney death with 239 events (4.5%) in the sotagliflozin group and 306 events (5.7%) in the placebo group (HR [95% CI] = 0.77 [0.65, 0.91], p=0.0023). Results were consistent when using different eGFR decline thresholds and when only including kidney death in composites (all p<0.01). The incidence of AKI was similar between treatment groups. Conclusions: In this exploratory analysis using the complete laboratory dataset, sotagliflozin reduced the risk of kidney and cardiorenal composite endpoints in patients with type 2 diabetes and CKD.

urology & nephrology